Patents by Inventor Marco Henneböhle

Marco Henneböhle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
    Patent number: 8236818
    Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: August 7, 2012
    Assignee: Santhera Pharmaceuticals (Schweiz) AG
    Inventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
  • Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
    Publication number: 20100249093
    Abstract: The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.
    Type: Application
    Filed: July 18, 2008
    Publication date: September 30, 2010
    Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AG
    Inventors: Marco Henneböhle, Holger Herzner, Michael Soeberdt, Philipp Weyermann, Sonja Nordhoff, Achim Feurer, Holger Deppe, Hervé Siendt, Miroslav Terinek, Christian Rummey
  • Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists
    Publication number: 20100093697
    Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.
    Type: Application
    Filed: March 28, 2008
    Publication date: April 15, 2010
    Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AG
    Inventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
  • Alpha-keto carbonyl calpain inhibitors
    Publication number: 20060258598
    Abstract: The present invention relates to novel ?-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all conditions where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease (MCP) also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.
    Type: Application
    Filed: March 3, 2004
    Publication date: November 16, 2006
    Inventors: Holger Herzner, Philipp Weyermann, Andreas Sprecher, Marco Henneböhle, Cyrille Lescop, Hervé Siendt